Pharmaron Beijing : INSIDE INFORMATION ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.*

康龍化成（北京）新藥技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Pharmaron Beijing Co., Ltd (the "Company") pursuant to Rule 13.09(2) of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company attended the ceremony held by the Development and Construction Management Committee of the Hangzhou Bay New Area of Ningbo, Zhejiang* (浙江省寧波杭州灣新區開發建 設管理委員會) in relation to the potential investment in Hangzhou Bay New Area* (杭州灣新區)

on August 28, 2020. The Company has intentions to construct a facility in the Hangzhou Bay New Area with a total estimated investment amount of RMB3.5 billion (the "Potential Construction"). It is currently expected that the facility will be used for research and development services for discovery, development and manufacturing of biologics. The Company will implement the construction plan step-by-step.

There is no assurance of the Company that any transactions or plan referred to in this announcement will materialize or eventually be consummated. Shareholders of the Company and potential investors should note that the Potential Construction is subject to a number of internal and external factors. The Company has not entered into any form of memorandum of understanding or agreement in relation to the Potential Construction and the Potential Construction may or may not proceed. The Company will make announcements of material developments in relation to the Potential Construction as and when appropriate in accordance with the Listing Rules. Investors of the Company are advised to pay attention to further announcements made by the Company and investment risks.

1

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the preliminary assessment of the currently available information by the Group's management. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's shares.

By order of the Board

Pharmaron Beijing Co., Ltd.*

康龍化成（北京）新藥技術股份有限公司

Dr. Lou Boliang

Chairman

Beijing, the PRC

August 28, 2020

As at the date of this announcement, the Board of Directors comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors; Mr. CHEN Pingjin, Mr. HU Baifeng, Mr. LI Jiaqing and Mr. ZHOU Hongbin as non-executive Directors; Mr. DAI Lixin, Ms. CHEN Guoqin, Mr. TSANG Kwan Hung Benson and Mr. YU Jian as independent non-executive Directors.

• For identification purposes only

2